Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 29 (1) , 5-12
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (rhFGF21) Modified with Polyethylene GlycolPLOS ONE, 2011
- High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coliBMC Biotechnology, 2010
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia, 2009
- Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathyFEBS Letters, 2009
- Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese MiceDiabetes, 2009
- Targeting Hepatic Glucokinase in Type 2 DiabetesDiabetes, 2009
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005
- Insulin GlargineDrugs, 2001
- Fibroblast growth factors and their receptorsBiochemistry and Cell Biology, 1997
- Pancreatic β-Cell-specific Targeted Disruption of Glucokinase GeneJournal of Biological Chemistry, 1995